MX2019014687A - Formulaciones farmaceuticas orales de remogliflozina. - Google Patents
Formulaciones farmaceuticas orales de remogliflozina.Info
- Publication number
- MX2019014687A MX2019014687A MX2019014687A MX2019014687A MX2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A
- Authority
- MX
- Mexico
- Prior art keywords
- remogliflozin
- release layer
- pharmaceutically acceptable
- immediate release
- pharmaceutical formulations
- Prior art date
Links
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 title abstract 2
- 229940126844 remogliflozin Drugs 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 abstract 2
- 229950011516 remogliflozin etabonate Drugs 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 1
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a una formulación oral de liberacion inmediata de remogliflozina o sales farmaceuticamente aceptables de la misma administrada en pacientes que la necesitan, para el tratamiento de la diabetes mellitus. La presente invencion se refiere ademas a una formulación farmacéutica que comprende una combinacion sinérgica de etabonato de remogliflozina y clorhidrato de metformina. En una modalidad preferida, la invencion se refiere a un comprimido bicapa que comprende una capa de liberacion inmediata y una capa de liberacion prolongada en donde la capa de liberacion inmediata comprende etabonato de remogliflozina o sus sales farmaceuticamente aceptables y la capa de liberacion prolongada comprende metformina o una sal farmaceuticamente aceptable de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721020166 | 2017-06-08 | ||
| PCT/IB2018/054091 WO2018198102A1 (en) | 2017-06-08 | 2018-06-07 | Oral pharmaceutical formulations of remogliflozin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014687A true MX2019014687A (es) | 2020-10-15 |
Family
ID=63919598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014687A MX2019014687A (es) | 2017-06-08 | 2018-06-07 | Formulaciones farmaceuticas orales de remogliflozina. |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20200013719A (es) |
| CN (1) | CN110753540A (es) |
| BR (1) | BR112019026029A2 (es) |
| MX (1) | MX2019014687A (es) |
| PH (1) | PH12019502767A1 (es) |
| WO (1) | WO2018198102A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017056A2 (pt) * | 2018-02-21 | 2020-12-15 | Glenmark Pharmaceuticals Limited | Composição farmacêutica compreendendo remogliflozina e um agente antidiabético |
| WO2019162841A1 (en) * | 2018-02-21 | 2019-08-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical composition comprising remogliflozin for treatment of diabetes mellitus |
| WO2020182792A1 (en) | 2019-03-12 | 2020-09-17 | Dsm Ip Assets B.V. | Coated coacervate capsules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
| CN105193761B (zh) * | 2009-11-13 | 2019-12-06 | 阿斯利康(瑞典)有限公司 | 双层片剂 |
| CN103153288B (zh) * | 2010-07-09 | 2017-02-15 | 詹姆斯·特林卡·格林 | 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统 |
-
2018
- 2018-06-07 PH PH1/2019/502767A patent/PH12019502767A1/en unknown
- 2018-06-07 BR BR112019026029-3A patent/BR112019026029A2/pt not_active IP Right Cessation
- 2018-06-07 CN CN201880038198.9A patent/CN110753540A/zh active Pending
- 2018-06-07 MX MX2019014687A patent/MX2019014687A/es unknown
- 2018-06-07 KR KR1020197038666A patent/KR20200013719A/ko not_active Ceased
- 2018-06-07 WO PCT/IB2018/054091 patent/WO2018198102A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200013719A (ko) | 2020-02-07 |
| WO2018198102A1 (en) | 2018-11-01 |
| CN110753540A (zh) | 2020-02-04 |
| BR112019026029A2 (pt) | 2020-06-23 |
| PH12019502767A1 (en) | 2020-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200154A1 (ar) | مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1 | |
| CR9737A (es) | Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) sus sales. | |
| JP2015523407A5 (es) | ||
| AR082091A1 (es) | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| MX2020011961A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| CO2020000240A2 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| DOP2019000070A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| MX2019014687A (es) | Formulaciones farmaceuticas orales de remogliflozina. | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| CO7250447A2 (es) | Forma de medicamento para liberar los ingredientes activos | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| PA8669801A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
| MX2019003362A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. | |
| HN2010001775A (es) | Composicion farmaceutica oral que comprende la combinacion de una sal de keterolaco y vitaminas del complejo b | |
| MX2021011795A (es) | Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble. | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib | |
| AR075058A1 (es) | Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion |